In this study, we are trying to see if vitamin B6 can minimize the amplified blood pressure response to exercise following ischemia-reperfusion injury. We are interested in a protein called P2X3, of which function can be blocked by vitamin B6, in the neurons of our nervous system. It is very important for blood pressure regulation. We would like to see if the P2X3 plays a role in patients' rising blood pressure during exercise. The results of the proposed studies will provide a base for those two potential economic and non-invasive inventions to improve the overall health and well-being of PAD patients.

Start Date01 Sep 2024

Sponsor / Collaborator

Hershey Medical Center

[+1]

NCT05994742 / Not yet recruitingPhase 3IIT

Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition

Malnutrition underlies 45% of child deaths, and has far-reaching educational, economic and health consequences. Severe acute malnutrition (SAM) affects 17 million children globally and is the most life-threatening form of malnutrition. Community-based management of acute malnutrition using ready-to-use therapeutic food (RUTF) has transformed outcomes for children with uncomplicated SAM, but those presenting with poor appetite or medical complications (categorised as having 'complicated' SAM) require hospitalisation. Data show that pneumonia, diarrhoea and malaria are leading causes of death in children with complicated SAM after discharge from hospital. High risk of infectious deaths suggests that sustained antimicrobial interventions may reduce mortality following discharge from hospital. Furthermore, children with complicated SAM respond less well to nutritional rehabilitation, and oftentimes are discharged to a home environment characterised by poverty and multiple caregiver vulnerabilities including depression, low decision making autonomy, lack of social support, gender-restricted family relations, and competing demands on scarce resources. Caregivers have to navigate diverse challenges that impede engagement with clinical care after discharge from hospital. The objective is to address the biological and social determinants of multimorbidity in children with complicated SAM by developing multimodal packages of interventions and testing them in a 5-arm adaptive randomized controlled clinical trial, with death/hospitalization or failed nutritional recovery as the primary outcome.

Start Date01 Mar 2024

Sponsor / Collaborator

Queen Mary University of London

[+7]

NCT06390787 / CompletedPhase 2/3IIT

Enhancing Antiemetic Efficacy: A Randomized Trial of Vitamin B6 and Metoclopramide Combination Therapy Versus Traditional Regimens

This study investigates the effectiveness of combining vitamin B6 (pyridoxine) and metoclopramide compared to standard antiemetic treatments for managing nausea and vomiting. Through a prospective, randomized controlled trial involving adult patients with diverse causes of nausea and vomiting, we aim to evaluate the frequency, severity, and tolerability of the B6 and metoclopramide combination. By elucidating its comparative efficacy against established antiemetics, this research seeks to provide evidence-based guidance for clinicians in selecting optimal treatment regimens tailored to individual patient needs, ultimately enhancing the management of nausea and vomiting across various medical conditions.

Start Date30 Jan 2024

Sponsor / Collaborator

University of Baghdad

100 Clinical Results associated with Pyridoxine Hydrochloride

100 Translational Medicine associated with Pyridoxine Hydrochloride

100 Patents (Medical) associated with Pyridoxine Hydrochloride

10,635

Literatures (Medical) associated with Pyridoxine Hydrochloride

01 Oct 2108·Psychiatria DanubinaQ4 · MEDICINE

HOMOCYSTEINE, PYRIDOXINE, FOLATE AND VITAMIN B12 LEVELS IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

Q4 · MEDICINE

Article

Author: Olcay Güngör ; Nilfer Şahin ; Ergül Belge Kurutaş ; Hatice Altun

BACKGROUNDIn our study, we aimed to evaluate the serum homocysteine levels, pyridoxine, folate and vitamin B12 levels in children with attention deficit hyperactivity disorders (ADHD).SUBJECTS AND METHODSThis study included 30 newly diagnosed drug-naive children with ADHD (23 males and 7 female, mean age 9.3±1.8 years) and 30 sex-and age matched healthy controls. The diagnosis of ADHD was made according to DSM-V criteria. Children and adolescents were administered the Schedule for Affective Disorders and Schizophrenia for School Aged Children, Present and Lifetime Version, the Conners' Parent Rating Scale-Revised, Long Form, the Conners' Teacher Rating Scale and the Wechsler Intelligence Scale for Children Revised (WISC-R) for all participants. Homocysteine, pyridoxine, folate and vitamin B12 levels were measured with enzyme-linked immunosorbent assay.RESULTSHomocysteine, pyridoxine, folate and vitamin B12 levels were significantly lower in children with ADHD compared with their controls (p<0.05). A positive significant correlation was observed between the all WISC-R scores and vitamin B12 level in patients (r=0.408, p=0.025).CONCLUSIONSThe results obtained in this study showed that reduced homocysteine, pyridoxine, folate and vitamin B12 levels could be a risk factor in the etiology of ADHD.

31 Dec 2024·Epigenetics

One-carbon metabolism nutrients impact the interplay between DNA methylation and gene expression in liver, enhancing protein synthesis in Atlantic salmon

Article

Author: Saito, Takaya ; Espe, Marit ; Bock, Christoph ; Adam, Anne-Catrin ; Skjaerven, Kaja H ; Fernandes, Jorge M O ; Thomsen, Tårn H ; Vikeså, Vibeke

Supplementation of one-carbon (1C) metabolism micronutrients, which include B-vitamins and methionine, is essential for the healthy growth and development of Atlantic salmon (Salmo salar). However, the recent shift towards non-fish meal diets in salmon aquaculture has led to the need for reassessments of recommended micronutrient levels. Despite the importance of 1C metabolism in growth performance and various cellular regulations, the molecular mechanisms affected by these dietary alterations are less understood. To investigate the molecular effect of 1C nutrients, we analysed gene expression and DNA methylation using two types of omics data: RNA sequencing (RNA-seq) and reduced-representation bisulphite sequencing (RRBS). We collected liver samples at the end of a feeding trial that lasted 220 days through the smoltification stage, where fish were fed three different levels of four key 1C nutrients: methionine, vitamin B6, B9, and B12. Our results indicate that the dosage of 1C nutrients significantly impacts genetic and epigenetic regulations in the liver of Atlantic salmon, particularly in biological pathways related to protein synthesis. The interplay between DNA methylation and gene expression in these pathways may play an important role in the mechanisms underlying growth performance affected by 1C metabolism.

31 Dec 2024·Gut Microbes

A synthetic microbial consortium protects against obesity by regulating vitamin B6 metabolism

Article

Author: Wang, Lina ; Kang, Guangbo ; Qiang, Guifen ; Huang, He ; Gao, Mengxue ; Wu, Yili ; Chen, Xiuzhao

Constructing synthetic microbial consortia is a challenging task but holds enormous potential for various applications. Our previous droplet-based microfluidic approach allowed for the isolation of bacteria that could utilize metabolites from an engineered bacterium BsS-RS06551 with anti-obesity potential, facilitating the construction of synthetic microbial consortia. Here, we identified a strain of Bifidobacterium pseudocatenulatum JJ3 that interacted with BsS-RS06551, and in vitro coculture showed that BsS-RS06551 was likely to interact with JJ3 through five dipeptides. Pathway analysis revealed that the vitamin B6 metabolism pathway was enriched in the coculture of BsS-RS06551 and JJ3 compared with the individual culture of BsS-RS06551. Additionally, we confirmed that the administration of JJ3 significantly alleviated obesity and related disorders in mice fed a high-fat diet. Notably, continuous ingestion of the synthetic microbial consortium comprising BsS-RS06551 and JJ3 not only exhibited a more pronounced impact on alleviating obesity compared to the individual administration of BsS-RS06551 or JJ3 but also enriched the population of Bifidobacterium longum and perturbed the vitamin B6 metabolism pathway in the gut. Synthetic microbial consortia represent a promising frontier for synthetic biology, and our strategy provides guidance for constructing and applying such consortia.

News (Medical) associated with Pyridoxine Hydrochloride

10 May 2024

·www.fiercehealthcare.com

New specialty care provider Harmonia Healthcare opens clinic to treat extreme morning sickness

Harmonia Healthcare's chief scientific officer, Marlena Fejzo, Ph.D., will also leverage her groundbreaking discovery of the hormone associated with HG to drive innovations in prognostics, prevention and treatments. Harmonia Healthcare, a new provider focused on specialty women’s health, has opened a clinic in New Jersey to treat hyperemesis gravidarum (HG). HG can bring nausea and vomiting during pregnancy severe enough to prevent proper food intake and can lead to weight loss, dehydration and ultimately hospitalization. It can cause complications for mothers and their babies and is estimated to affect up to nearly 11% of pregnant women. Harmonia’s new clinic will offer evidence-based treatments and educate patients on the latest science around HG. Its offerings include medication and vitamin infusion, electrolyte replacement plans, prescription management, diagnostic bloodwork and telehealth. A second clinic is planned to open in New York City this fall. The clinic does not require referrals. Its chief scientific officer, Marlena Fejzo, Ph.D., a women’s health researcher with lived experience of HG, will also leverage her and colleagues' groundbreaking discovery of the hormone associated with the condition—GDF15—to drive innovations in prognostics, prevention and treatment. Fejzo was a 2023 Fiercest Women in Life Sciences awardee. “We really want to fix the broken care model in women’s health and improve care,” Fejzo told Fierce Healthcare. “We hope to expand this to be the future of care for these undertreated and underdiagnosed diseases.” Harmonia’s online platform will offer educational resources and eventually telehealth, though women should still ideally first come into the clinic in person. The current status quo for women with HG is unacceptable and costly, Fejzo says. If they end up in an emergency room, they are treated with fluids or antiemetic drugs and released. But because HG causes persistent nausea and vomiting, women need persistent medication management, Fejzo argues. If they are discharged without a prescription, many will inevitably wind up back in the hospital again; 60% of women have multiple hospital visits, per Fejzo. And, while HG is starting to be diagnosed properly more often, Fejzo said, it can still be misdiagnosed or not diagnosed at all. “A lot of people think that it’s just regular nausea and vomiting and that everything’s going to be fine … when actually there are really adverse outcomes associated with HG for the mother and the baby,” Fejzo said. During a recent conference, Fejzo said she discovered ER doctors affiliated with Harvard discharge HG patients without a prescription. Their justification for it was that the medications might make them tired, and then they would have to miss work. “That’s a real misunderstanding of HG,” Fejzo said, adding that if Harvard-affiliated docs are doing it, “I assume it is common.” RELATED: New study finds cause and potential treatment for dangerous morning sickness Part of the reason Fejzo believes this is happening is due to a famous historic incident known as the thalidomide disaster. After women being treated with thalidomide for nausea had babies with birth defects, it launched a widespread hesitancy to prescribe medications during pregnancy, Fejzo said. There also remains a misguided belief that HG is psychological or resolves on its own. And because HG typically starts early in pregnancy, many women see ER docs before even seeing their obstetrician, meaning many providers may not be aware of how sick their patients have really been. Obstetricians are also generally not trained to ask their patients about their levels of nausea and vomiting—and patients, too, may not talk about it, Fejzo explained. To address this, Harmonia will be monitoring women receiving medication management and coordinating with their other providers, like OB-GYNs, midwives and doulas. The goal is to intervene as early as possible with more aggressive treatment before the condition spirals out of control. The best medications for HG being prescribed off-label include Zofran, Phenergan and Reglan, according to Fejzo. Yet doctors usually begin with doxylamine and pyridoxine, as recommended by the American College of Obstetricians and Gynecologists, which Fejzo says are “pretty much a placebo for HG.” By serving patients with HG, Harmonia will have the infrastructure in place to run clinical trials on potential new treatments, Fejzo said. She is already advising NGM Bio, which recently announced it is interested in testing its drug NGM120 in HG patients. While Fejzo doesn’t anticipate challenges with patients getting their scripts filled, Harmonia providers will educate patients on how to have conversations with pharmacists in case they do run into pushback. In recent years, pharmacists have sometimes refused to fill opioid prescriptions with doses they perceived as too high or poorly monitored by the prescriber. One of the country’s only other clinics in this space, Alabama’s Morning Sickness Clinic, claims its model has led to a 95% reduction in ER visits and a 90% decrease in total cost of care. Its co-founder, an emergency medicine physician, is one of Harmonia’s clinical advisers. Harmonia eventually hopes to expand to serve other under-researched women’s health conditions. While the company does not currently plan to pursue formal health system partnerships, it hopes that its clinics will come to be known locally as the go-to expert for these conditions. And, while it isn’t yet, Harmonia plans to be working with commercial and Medicaid insurance plans by the end of this year.

04 Apr 2024

·www.globenewswire.com

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuriaSAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society for Inherited Metabolic Disorders (SIMD) in Charlotte, North Carolina from April 14-17, 2024, and Genetic Metabolic Dieticians International (GMDI) in Charlotte, North Carolina from April 17-20, 2024. At SIMD and GMDI, the Company will present the trial design of the pivotal Phase 3 HARMONY Study of pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of classical HCU. Additionally, the Company will share insights on the development of an innovative tool used for dietary management and monitoring in the Phase 3 HARMONY Study and open-label extension ENSEMBLE Study, and the positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase in classical HCU. “Classical HCU is an isolating and devastating rare disorder with very limited treatment options, including adherence to highly restrictive diets, leaving patients and their caregivers with immense challenges,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “We look forward to participating at both of these prestigious metabolic medical meetings, and we are excited about our work pioneering the first potential disease-modifying treatment for the thousands of people affected by classical HCU.” SIMD Poster Presentations Latest Results From the COMPOSE Phase 1/2 Trial For the Treatment of Classical Homocystinuria (HCU) Using Pegtibatinase, a Novel Investigational Enzyme Replacement TherapyPoster: 139Abstract Category: Innovative TherapiesSymphony Ballrooms 4-7; April 15, 2024, 8-9 p.m. ET Pegtibatinase, an Investigational Enzyme Replacement Therapy, For The Treatment of Classical Homocystinuria (HCU): Design of the HARMONY Phase 3 Study Poster: 147Abstract Category: Innovative Therapies Symphony Ballrooms 4-7; April 15, 2024, 8-9 p.m. ET Economic Burden of Classical Homocystinuria in the United StatesPoster: 48Abstract Category: Clinical Care/ResearchSymphony Ballrooms 4-7; April 15, 2024, 7-8 p.m. ET Clinical Burden of Classical Homocystinuria in the United States: A Retrospective Claims Analysis Poster: 64Abstract Category: Clinical Care/ResearchSymphony Ballrooms 4-7; April 15, 2024, 7-8 p.m. ET Association Between Homocysteine and Clinical Outcomes in Patients with Classical Homocystinuria: A Systematic Literature ReviewPoster: 68Abstract Category: Clinical Care/ResearchSymphony Ballrooms 4-7; April 15, 2024, 7-8 p.m. ET GMDI Poster Presentations Latest Results from the COMPOSE Phase 1/2 Trial of Pegtibatinase, a Novel Investigational Enzyme Replacement Therapy for Classical Homocystinuria (HCU) Poster: 10April 18, 2024, 4:30-5:15 p.m. ET Novel Tool for Dietary Management and Monitoring in Clinical Trials of Pegtibatinase, an Investigational Enzyme Replacement Therapy for Classical Homocystinuria Poster: 16April 18, 2024, 4:30-5:15 p.m. ET Novel Dietary Management Strategies for Classical Homocystinuria (HCU) in HARMONY/ENSEMBLE Phase 3 Studies of Pegtibatinase, an Investigational Enzyme Replacement Therapy Poster: 33April 18, 2024, 5:15-6 p.m. ET About Classical Homocystinuria Classical homocystinuria (HCU) is a rare genetic metabolic disorder caused by a deficiency in the enzyme cystathionine beta synthase (CBS). CBS is a pivotal enzyme that is essential for the management of methionine and cysteine in the body. Classical HCU leads to toxic levels of homocysteine that can result in life-threatening thrombotic events such as stroke, pulmonary embolism and deep vein thrombosis, ophthalmologic and skeletal complications, as well as developmental delay. Current treatment options are limited to protein-restricted diet and use of vitamin B6 and betaine. About Pegtibatinase Pegtibatinase is an investigational PEGylated, recombinant enzyme replacement therapy designed to address the underlying cause of classical homocystinuria (HCU). In preclinical studies, pegtibatinase has demonstrated an ability to reduce total homocysteine levels and improve clinical parameters. Pegtibatinase is currently advancing in the ongoing Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. In May 2023, the Company announced that data from four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment. To date, the pegtibatinase program has been granted Breakthrough Therapy designation, Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Drug designation in the U.S. and Europe. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com Forward Looking Statements This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “anticipate,” “believe,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “will” or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria, references to the HARMONY study and the other studies described herein, including statements regarding expectations related thereto, and statements regarding the development of an innovative tool used for dietary management and monitoring. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to the timing and outcome of the HARMONY study and the other studies described herein; risks and uncertainties associated with the regulatory review and approval process, risks associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. The Company faces risks related to its business and finances in general; risks related to the commercial launch of a new product; risks associated with market acceptance of FILSPARI and other current and future products, including efficacy, safety, price, reimbursement and benefit over competing therapies; and the risk that the Company’s clinical candidates will not be found to be safe or effective and that current or anticipated future clinical trials will not proceed as planned. Specifically, the Company faces risks related to the timing and potential outcome of the FDA’s potential acceptance for filing and review of the sNDA submission for full approval of FILSPARI in IgAN, and the timing and potential outcome of the European Commission’s decision regarding conditional marketing authorization of sparsentan for IgAN. There is no guarantee that the FDA will accept the sNDA submission for filing, that the European Commission will grant conditional marketing authorization of sparsentan for IgAN, or that regulators will grant full approval of sparsentan for IgAN or FSGS. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company's products, and technological changes that may limit demand for the Company's products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission. Contact Info Media:888-969-7879 mediarelations@travere.comInvestors:888-969-7879 IR@travere.com

Orphan DrugBreakthrough TherapyPhase 3Fast TrackClinical Result

31 Jan 2024

·www.prnewswire.com

Relax'in Naturally Reinforces Mental Health

Synevit®'s Natural Mood Support Supplement Uses a Unique Combination of Ingredients to Balance Serotonin and Dopamine Synthesis FORT LAUDERDALE, Fla., Jan. 31, 2024 /PRNewswire/ -- Mental health has been in the spotlight in recent years. As conditions like anxiety and depression become more common and diagnosable, it's important for consumers to have options to address them based on the severity of each case. With milder mental health concerns, solutions like Relax'in can help naturally restore a sense of peace and balance to everyday life. In 2019, WHO reported that one in eight people around the world struggled with a mental disorder, with anxiety and depression standing out as the most common struggle. Those numbers rose after the pandemic and are noticeably higher in the United States, in particular. In 2021, the National Institute of Health reported that one in five U.S. adults was living with a mental illness, while Johns Hopkins Medicine highlights that more than one in four American adults suffer from a diagnosable mental disorder each year. With mental health concerns on the rise, it's important for consumers to have options. There's no doubt that stronger pharmaceuticals are needed at times, and every individual should consult with their primary care physician when diagnosing a mental health concern. However, there are times when a gentler (though still targeted) natural solution is ideal. Relax'in is a natural mood support product that is perfect for these occasions. The science-backed formula is a natural mood booster that uses key ingredients to improve the synthesis of the neurotransmitters serotonin and dopamine within the body. For instance, 5-Hydroxytryptophan (5-HTP) helps improve the production of serotonin in the brain. Among other things, vitamin B6 and Tyrosine are also critical for the production of serotonin as well as dopamine. Relax'in's unique combination of these and other ingredients work together to improve mood and memory. They also increase concentration and logical thinking and help with sleep and control of fine movements and motor skills. Restoring mental health balance with a natural alternative like Relax'in can also help avoid harmful habits rooted in mental instability, such as excessive alcohol consumption and smoking. All that's required with Relax'in is to take one to two tablets per day after a meal. From there, its extended-release formula continues to work throughout the day. The product is vegan, gluten-free, GMP-certified, and made in the USA. In addition, each dose comes in blister packs to ensure that the ingredients don't degrade and remain potent and effective for several years. "Our motto is 'Technology in Synergy with Nature®," explains SYNEVIT® founder George Cvetkovski. "We constantly engage in consultation with doctors and pharmacists to seek the ideal ratio of natural ingredients. This ensures that Relax'in provides genuine, powerful, and natural support for those with mental health concerns. In many cases, this helps our customers regain and maintain mental clarity and balance without the need to resort to stronger pharmaceuticals." About SYNEVIT® Launched in 1998 by CEO George Cvetkovski, SYNEVIT® traces its roots to North Macedonia (ex: Yugoslavia). The brand is currently headquartered out of North Macedonia with offices in Serbia and Rochester, New York. SYNEVIT® is an in-house brand of vitamins and minerals with unique, perpetually improved formulas informed by on-staff doctors and pharmacists and designed for therapeutic effect in patients. Learn more at synevit.net. George Cvetkovski [email protected] (02) 3225 843 SOURCE Synevit

100 Deals associated with Pyridoxine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Pyridoxine Hydrochloride	A11HA02	DB00165

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin B 6 Deficiency	US	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Progressive pulmonary fibrosis	Phase 2	CN	Shanxi Bethune Hospital	01 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed	Not Applicable	-	5,612	Vitamin B6 (Older adults (≥65y))	xuuxvvzxic(wvzlvijvqt) = jjkptfhyuy xxmfvjauni (pfnzycmwlo )	-	20 Oct 2022
				Vitamin B6 (Younger adults (<65y))	xuuxvvzxic(wvzlvijvqt) = hvhibwighe xxmfvjauni (pfnzycmwlo )
ASCO2019	Not Applicable	Refractory cytopenia with multilineage dysplasia and ringed sideroblasts	161	Vitamin B6 replacement	xycujiqxjb(mpoztwopwx) = boqwpuitnk uqrnlgcmts (ckiganhgbw ) View more	Positive	26 May 2019
				No Vitamin B6 replacement	xycujiqxjb(mpoztwopwx) = qfkiqjknyt uqrnlgcmts (ckiganhgbw ) View more
SSIEM2022	Not Applicable	Pyridoxine-Dependent Epilepsy 6-oxo-pipecolate \| 2S,6S-2S,6R-oxopropylpiperidine-2-carboxylic acid	-	Pyridoxine and lysine reduction therapies (LRT)	dfmaducqix(sthegkuptl) = pvcodnazwv baqsoyfwiq (pgbtpyqhpy, 1.7 - 42.0)	-	30 Aug 2022
Pubmed \| J Intern Med	Not Applicable	homocysteine	6,837	Folic acid + vitamin B12 + vitamin B6	(vnilsuhkul): hazard ratio = 1.07 (95% CI, 0.95 - 1.21) View more	-	01 Oct 2010
				Placebo
VISP Trial (ISC2014)	Not Applicable	Stroke	3,680	Best medical/surgical management + daily vitamin B6, vitamin B12, and folic acid supplementation	acialrzmnp(notsrdyzco) = emzdgmthzk eakfkoswlm (foqwvucarh )	-	01 Feb 2014
NCT01281878 (Pubmed \| Clin J Am Soc Nephrol)	Phase 2	Primary Hyperoxaluria Type 1	12	Vitamin B6	ebcapbvizi(plxzrcidvy) = qnmequfjti tlwwtetqot (viowtkgipf ) View more	-	01 Mar 2014
NCT00446147 (Pubmed \| J Urol)	Phase 3	Hand-Foot Syndrome	389	Pyridoxine	tqutynpvqe(eegdbhhrtl) = pyyjlhvvug luaotrsfra (ibwpukjqui )	Negative	20 Aug 2010
				Placebo	tqutynpvqe(eegdbhhrtl) = ckewuivghr luaotrsfra (ibwpukjqui )
NCT00486213 (Pubmed \| JAMA Oncol)	Phase 3	Hand-Foot Syndrome vitamin B12 levels \| genetic polymorphisms	210	Pyridoxine	elcajbpixs(pwudorxeua) = romuwtcojs tfectiluas (yzuzkatvba )	-	01 Nov 2017
				Placebo	elcajbpixs(pwudorxeua) = agbrtvuajw tfectiluas (yzuzkatvba )
EADV2023	Not Applicable	-	61	Oral biotin	rilmekbmta(bmofvifcea) = xoukwwfvix tubdromgcu (pqkfczctgu ) View more	Positive	11 Oct 2023
				Pyridoxine	rilmekbmta(bmofvifcea) = fhdsusfihj tubdromgcu (pqkfczctgu ) View more
Alienor Study (ARVO2022)	Not Applicable	Age Related Macular Degeneration	963	Vitamin B5	hddsbwvixd(frgvprtdub) = lnklxtavud ajhtwdauix (kswabrsrge, 1.84mg)	-	01 May 2022
				Vitamin B6	hddsbwvixd(frgvprtdub) = cbjxdsewur ajhtwdauix (kswabrsrge, 0.60mg)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis